إعلان
إعلان

SMMT

SMMT logo

Summit Therapeutics Inc. Common Stock

19.70
USD
برعاية
+0.87
+4.63%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

19.55

-0.15
-0.77%

تقارير أرباح SMMT

النسبة الإيجابية المفاجئة

SMMT تفوق 3 من 13 آخر التقديرات.

23%

التقرير التالي

بيانات التقرير القادم
٢٣ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$102.00M
/
-$0.06
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/
-80.65%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
-25.00%

Summit Therapeutics Inc. Common Stock earnings per share and revenue

On ٢٠ أكتوبر ٢٠٢٥, SMMT reported earnings of -0.31 USD per share (EPS) for Q3 25, missing the estimate of -0.13 USD, resulting in a -130.48% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.55% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 19 المحللين forecast an EPS of -0.06 USD, with revenue projected to reach 102.00 مليون USD, implying an نقصان of -80.65% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
٢٦ ديسمبر ٢٠٢٥ إلى ربع سنوي4 25
تقدير
-$0.49
الفعلي
-
مفاجئة
-
الأسئلة الشائعة
For Q3 2025, Summit Therapeutics Inc. Common Stock reported EPS of -$0.31, missing estimates by -130.48%, and revenue of $0.00, 0% as expectations.
The stock price moved down -4.55%, changed from $20.99 before the earnings release to $20.04 the day after.
The next earning report is scheduled for ٢٣ فبراير ٢٠٢٦.
Based on 19 المحللين, Summit Therapeutics Inc. Common Stock is expected to report EPS of -$0.06 and revenue of $102.00M for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان